Phenotypic Diversity in COVID-19

COVID-19 的表型多样性

• 批准号: 10158887
• 负责人: GARRET A FITZGERALD
• 金额: $ 63.39万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-07-01 至 2021-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10158887
• 关键词: Adult; Award; Biological Models; COVID-19; Cell model; Childhood; Clinical Sciences; Disease; Fostering; Funding; Growth; Home environment; Human; Institutes; Parents; Phenotype; Physiology; Research; Research Personnel; Therapeutic; Translational Research; drug action; translational medicine

ABSTRACT OF THE FUNDED PARENT AWARD The Institute for Translational Medicine and Therapeutics is the academic home for the CTSA in Penn. For the past decade the specific aims of ITMAT have been and remain (i) to increase the number of investigators capable of pursuing their research between proof of concept in cells and model systems and (ii) elucidation of the mechanisms of human physiology, disease or drug action through intense phenotyping in small numbers of people. The two priorities of our CTSA are to foster the field of translational therapeutics and to bridge the pediatric to adult divide across the entire spectrum of clinical and translational science. This section describes how these priorities have influenced the growth of this CTSA Hub and outlines our plans for the coming funding period.

受资助家长奖摘要 转化医学和治疗研究所是 CTSA 位于宾夕法尼亚州的学术所在地。对于 过去十年，ITMAT 的具体目标始终是 (i) 增加有能力的调查人员数量 在细胞和模型系统的概念验证和（ii）阐明之间进行研究 通过少量的强烈表型分析人类生理学、疾病或药物作用的机制 人们。我们的 CTSA 的两个优先事项是培育转化治疗领域并弥合 从儿科到成人的划分跨越了整个临床和转化科学领域。本节描述 这些优先事项如何影响 CTSA 中心的发展，并概述我们的未来融资计划 时期。